Botulinum Toxin Type A for Neuroma Pain

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Neuroma

In brief

The purpose of this study is to determine if botulinum toxin type A (Btx-A) is an effective treatment for painful neuromas. The ideal therapy for painful neuromas would be effective, non-addictive, safe, localized, and cost-effective treatment. At the same time, the therapy would also address the complex peripheral and central mechanisms. Btx-A is a potential treatment that addresses each of these requirements while preserving the existing sensation and function. Study Hypothesis: Btx-A injection relieves neuroma pain better than a placebo

Key facts

Study ID

NCT01374191

Run by

Southern Illinois University

People needed

0

Starts

2015-01-01

Expected to finish

2017-09-01

Last updated by the study team

2015-08-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female
• aged 18-75 years
• diagnosed with neuroma pain
• able to return/be available for follow-up evaluations
• willingness and ability to give informed consent

You may not qualify if…

• positive for HIV/AIDS or otherwise immunocompromised
• history of neuromuscular disease
• reported allergy to BOTOX®
• history or symptoms of any significant medical problem in the last year (i.e., bradycardia, impaired cardiovascular function, liver disease)
• symptoms of infection or illness with initial enrollment
• pregnant or lactating women
• unable or unwilling to maintain abstinence or use contraception for 28 days following all injections
• cognitively impaired patients unable to give informed consent

Where it is running

• Southern Illinois University School of Medicine — Springfield, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.